Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
2
50%
Ph phase_1
2
50%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (50.0%)
Phase 22 (50.0%)

Trials by Status

completed375%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia

NCT04964557
terminatedphase_1

To Assess the Pharmacokinetics, Safety, and Tolerability of AZD8233 in Participants With Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and Healthy Participants.

NCT05065463
completedphase_2

A Study of AZD8233 in Participants With Dyslipidemia

NCT04641299
completedphase_1

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.

NCT03593785

Clinical Trials (4)

Showing 4 of 4 trials
NCT04964557Phase 2

A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia

Completed
NCT05065463Phase 1

To Assess the Pharmacokinetics, Safety, and Tolerability of AZD8233 in Participants With Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and Healthy Participants.

Terminated
NCT04641299Phase 2

A Study of AZD8233 in Participants With Dyslipidemia

Completed
NCT03593785Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4